FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568344927> ?p ?o ?g. }

• W2568344927 endingPage "S1084" @default.
• W2568344927 startingPage "S1083" @default.
• W2568344927 abstract "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown antitumor efficacy and prolonged progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harboring EGFR activation mutations; however, acquired resistance often develops limiting clinical efficacy. ASP8273 is an irreversible, once-daily (QD), orally available TKI with activity against both activating and resistance EGFR mutations (ex19del, L858R, T790M). Preliminary findings from Phase 1 and Phase 2 trials in the US, Japan, Taiwan, and Korea have demonstrated antitumor activity and overall tolerability of ASP8273 at doses of 100mg–300mg. This global, multicenter, open-label, randomized, Phase 3 study will enroll ∼600 adult subjects with Stage IIIB/IV NSCLC with EGFR-activating mutations (ex19del or L858R, with or without T790M) who have not been treated with an EGFR inhibitor TKI (NCT02588261). Subjects will be randomized 1:1 to treatment with either 300mg oral ASP8273 QD or erlotinib/gefitinib. Each site will select a comparator drug (150mg erlotinib QD or 250mg gefitinib QD) at the beginning of the study. Randomization will be stratified by ECOG status (0, 1, and 2), EGFR mutation (ex19del, L858R), comparator selected (erlotinib vs gefitinib), and race (Asian vs non-Asian). Subjects will not be enrolled if they harbor both ex19del and L858R. All subjects will begin treatment on Day 1 Cycle 1 and will continue on 28-day continuous dosing cycles until the subject discontinues (eg, due to radiologic progression as determined by RECIST or unacceptable toxicity). Dose reductions will be allowed for ASP8273 and erlotinib, but not for gefitinib. The primary study objective is PFS as assessed by independent radiological review (IRR); secondary study objectives are overall survival, best overall response rate, disease control rate and duration of response by IRR, safety/tolerability, and patient quality of life. An independent Data Monitoring Committee will oversee trial safety and the interim futility analysis. Enrollment for the trial began 26 February 2016; 46 subjects have been randomized as of 17 May 2016. Section not applicable. Section not applicable." @default.
• W2568344927 created "2017-01-13" @default.
• W2568344927 creator A5003515419 @default.
• W2568344927 creator A5006540113 @default.
• W2568344927 creator A5009951383 @default.
• W2568344927 creator A5024261346 @default.
• W2568344927 creator A5029802290 @default.
• W2568344927 creator A5037164044 @default.
• W2568344927 creator A5049719185 @default.
• W2568344927 creator A5050894934 @default.
• W2568344927 creator A5055074037 @default.
• W2568344927 creator A5059886787 @default.
• W2568344927 creator A5069395580 @default.
• W2568344927 creator A5073284312 @default.
• W2568344927 creator A5074545974 @default.
• W2568344927 creator A5089955257 @default.
• W2568344927 date "2017-01-01" @default.
• W2568344927 modified "2023-09-27" @default.
• W2568344927 title "P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFR Mut+ NSCLC" @default.
• W2568344927 doi "https://doi.org/10.1016/j.jtho.2016.11.1514" @default.
• W2568344927 hasPublicationYear "2017" @default.
• W2568344927 type Work @default.
• W2568344927 sameAs 2568344927 @default.
• W2568344927 citedByCount "1" @default.
• W2568344927 countsByYear W25683449272018 @default.
• W2568344927 crossrefType "journal-article" @default.
• W2568344927 hasAuthorship W2568344927A5003515419 @default.
• W2568344927 hasAuthorship W2568344927A5006540113 @default.
• W2568344927 hasAuthorship W2568344927A5009951383 @default.
• W2568344927 hasAuthorship W2568344927A5024261346 @default.
• W2568344927 hasAuthorship W2568344927A5029802290 @default.
• W2568344927 hasAuthorship W2568344927A5037164044 @default.
• W2568344927 hasAuthorship W2568344927A5049719185 @default.
• W2568344927 hasAuthorship W2568344927A5050894934 @default.
• W2568344927 hasAuthorship W2568344927A5055074037 @default.
• W2568344927 hasAuthorship W2568344927A5059886787 @default.
• W2568344927 hasAuthorship W2568344927A5069395580 @default.
• W2568344927 hasAuthorship W2568344927A5073284312 @default.
• W2568344927 hasAuthorship W2568344927A5074545974 @default.
• W2568344927 hasAuthorship W2568344927A5089955257 @default.
• W2568344927 hasBestOaLocation W25683449271 @default.
• W2568344927 hasConcept C104317684 @default.
• W2568344927 hasConcept C121608353 @default.
• W2568344927 hasConcept C126322002 @default.
• W2568344927 hasConcept C143998085 @default.
• W2568344927 hasConcept C156719811 @default.
• W2568344927 hasConcept C182707283 @default.
• W2568344927 hasConcept C185592680 @default.
• W2568344927 hasConcept C197934379 @default.
• W2568344927 hasConcept C2776256026 @default.
• W2568344927 hasConcept C2777506169 @default.
• W2568344927 hasConcept C2777930144 @default.
• W2568344927 hasConcept C2778087573 @default.
• W2568344927 hasConcept C2778375690 @default.
• W2568344927 hasConcept C2778820342 @default.
• W2568344927 hasConcept C2779438470 @default.
• W2568344927 hasConcept C2780580887 @default.
• W2568344927 hasConcept C2909325608 @default.
• W2568344927 hasConcept C31760486 @default.
• W2568344927 hasConcept C535046627 @default.
• W2568344927 hasConcept C55493867 @default.
• W2568344927 hasConcept C67705224 @default.
• W2568344927 hasConcept C71924100 @default.
• W2568344927 hasConcept C98274493 @default.
• W2568344927 hasConceptScore W2568344927C104317684 @default.
• W2568344927 hasConceptScore W2568344927C121608353 @default.
• W2568344927 hasConceptScore W2568344927C126322002 @default.
• W2568344927 hasConceptScore W2568344927C143998085 @default.
• W2568344927 hasConceptScore W2568344927C156719811 @default.
• W2568344927 hasConceptScore W2568344927C182707283 @default.
• W2568344927 hasConceptScore W2568344927C185592680 @default.
• W2568344927 hasConceptScore W2568344927C197934379 @default.
• W2568344927 hasConceptScore W2568344927C2776256026 @default.
• W2568344927 hasConceptScore W2568344927C2777506169 @default.
• W2568344927 hasConceptScore W2568344927C2777930144 @default.
• W2568344927 hasConceptScore W2568344927C2778087573 @default.
• W2568344927 hasConceptScore W2568344927C2778375690 @default.
• W2568344927 hasConceptScore W2568344927C2778820342 @default.
• W2568344927 hasConceptScore W2568344927C2779438470 @default.
• W2568344927 hasConceptScore W2568344927C2780580887 @default.
• W2568344927 hasConceptScore W2568344927C2909325608 @default.
• W2568344927 hasConceptScore W2568344927C31760486 @default.
• W2568344927 hasConceptScore W2568344927C535046627 @default.
• W2568344927 hasConceptScore W2568344927C55493867 @default.
• W2568344927 hasConceptScore W2568344927C67705224 @default.
• W2568344927 hasConceptScore W2568344927C71924100 @default.
• W2568344927 hasConceptScore W2568344927C98274493 @default.
• W2568344927 hasIssue "1" @default.
• W2568344927 hasLocation W25683449271 @default.
• W2568344927 hasOpenAccess W2568344927 @default.
• W2568344927 hasPrimaryLocation W25683449271 @default.
• W2568344927 hasRelatedWork W1964479812 @default.
• W2568344927 hasRelatedWork W1994499102 @default.
• W2568344927 hasRelatedWork W1995684830 @default.
• W2568344927 hasRelatedWork W2006984558 @default.
• W2568344927 hasRelatedWork W2017389411 @default.
• W2568344927 hasRelatedWork W2094111402 @default.
• W2568344927 hasRelatedWork W2186047679 @default.

• next